S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Inogen Stock Forecast, Price & News

-0.16 (-0.52%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
146,600 shs
Average Volume
254,380 shs
Market Capitalization
$699.90 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

Inogen logo

About Inogen

Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.


Inogen (NASDAQ:INGN) Sets New 12-Month Low at $26.70
January 10, 2022 |  americanbankingnews.com
Inogen Appoints Elizabeth Mora as Board Chairperson
December 30, 2021 |  finance.yahoo.com
Is Inogen, Inc. (NASDAQ:INGN) Potentially Undervalued?
December 23, 2021 |  finance.yahoo.com
Summary and Takeaways From COP26 - Yahoo Finance
December 21, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical appliances & supplies
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$308.49 million
Cash Flow
$0.58 per share
Book Value
$15.81 per share


Net Income
$-5.83 million
Pretax Margin




Free Float
Market Cap
$699.90 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.97 out of 5 stars

Medical Sector

656th out of 1,405 stocks

Surgical Appliances & Supplies Industry

14th out of 27 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Inogen (NASDAQ:INGN) Frequently Asked Questions

Is Inogen a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Inogen stock.
View analyst ratings for Inogen
or view top-rated stocks.

How has Inogen's stock been impacted by Coronavirus (COVID-19)?

Inogen's stock was trading at $40.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INGN shares have decreased by 24.2% and is now trading at $30.80.
View which stocks have been most impacted by COVID-19

When is Inogen's next earnings date?

Inogen is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Inogen

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) posted its earnings results on Thursday, November, 4th. The medical technology company reported $0.53 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.82. The medical technology company had revenue of $93.11 million for the quarter, compared to analyst estimates of $86.69 million. Inogen had a net margin of 3.21% and a trailing twelve-month return on equity of 3.11%. Inogen's revenue was up 25.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.08) earnings per share.
View Inogen's earnings history

What price target have analysts set for INGN?

6 brokerages have issued 12-month price targets for Inogen's shares. Their forecasts range from $40.00 to $75.00. On average, they expect Inogen's share price to reach $49.80 in the next year. This suggests a possible upside of 61.7% from the stock's current price.
View analysts' price targets for Inogen
or view top-rated stocks among Wall Street analysts.

Who are Inogen's key executives?

Inogen's management team includes the following people:
  • Nabil Shabshab, President, Chief Executive Officer & Director
  • Bart Sanford, Executive Vice President-Operations
  • Michael K. Sergesketter, Chief Financial Officer, Treasurer & Executive VP
  • Brenton Taylor, Executive Vice President-Engineering (LinkedIn Profile)
  • Stanislav Glezer, Chief Medical Officer & Executive Vice President

What is Scott Wilkinson's approval rating as Inogen's CEO?

70 employees have rated Inogen CEO Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among Inogen's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Who are Inogen's major shareholders?

Inogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo and Raymond Huggenberger.
View institutional ownership trends for Inogen

Which major investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, and Raymond Huggenberger.
View insider buying and selling activity for Inogen
or view top insider-selling stocks.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $30.80.

How much money does Inogen make?

Inogen has a market capitalization of $699.90 million and generates $308.49 million in revenue each year. The medical technology company earns $-5.83 million in net income (profit) each year or $0.49 on an earnings per share basis.

How many employees does Inogen have?

Inogen employs 938 workers across the globe.

What is Inogen's official website?

The official website for Inogen is www.inogen.com.

Where are Inogen's headquarters?

Inogen is headquartered at 326 BOLLAY DRIVE, GOLETA CA, 93117.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at (805) 562-0500 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.